(VIANEWS) – Shares of Novavax (NASDAQ: NVAX) fell by a staggering 27.49% in 21 sessions from $22.81 at 2022-10-26, to $16.54 at 14:11 EST on Friday, following the last session’s upward trend. NASDAQ is sliding 0.52% to $11,226.36, after two consecutive sessions in a row of gains.

Novavax’s last close was $17.03, 92.8% below its 52-week high of $236.50.

About Novavax

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Earnings per Share

Novavax’s trailing 12 months profit per share is $-7.27

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a company relative to shareholders’ equity, was negative at -898.2%.

Sales Growth

Novavax’s sales growth is 227.8% for the current quarter and 153.2% for the next.

Growth Estimates Quarters

For the current quarter, the company expects to grow by 136.7% and 113.3% respectively.

Moving Average

Novavax’s value is way under its 50-day moving average of $22.69 and way under its 200-day moving average of $50.83.


Novavax’s intraday variation average for the week and quarter ended last week was negative at 5.23% and negative at 0.02% respectively. It is positive however, at 5.50%.

Novavax had the highest average volatility amplitude at 5.23% last week, 5.19% last month and 5.50% in its final quarter.

More news about Novavax (NVAX).